Core cat vaccines include rabies, panleukopenia (a life-threatening viral gastroenteritis of kittens), calicivirus, and ...
Cats mostly spray to mark territory and communicate with other cats. Here's how to pinpoint the cause of indoor spraying and ...
Cats may have a higher risk of contracting COVID-19 than other pets. Here's how to protect your cat, treat symptoms at home, ...
Abstract: We propose an IoT-enabled miniaturized remote auto-injector supported by smartwatch health monitoring for the emergency medical treatment of allergy-induced anaphylaxis patients. A ...
Abstract: A novel shorted coaxial-line resonator (SCR) in substrate-integrated waveguide (SIW) configuration is integrated with a negative resistance circuit (NRC) to implement an ultrahigh Q-factor ...
The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 21.8% from $2.4bn in 2023 to $17bn by 2033. Image credit: Antonio Marca / Shutterstock.com Eli Lilly ...
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. With ...
Eli Lilly's shares have increased by about 10% over the past month. Clinical progress in the past few weeks has helped solidify its lead in the weight loss market. The company's prospects remain ...
It's been a volatile year for Eli Lilly (NYSE: LLY), with the pharmaceutical giant experiencing some setbacks. However, the drugmaker has been on a roll over the past month, with several catalysts ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...
Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster administration and broader access to immunotherapy. The FDA approved Merck’s ...
For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent protections expiring in 2028. The FDA has approved a subcutaneous version of ...